CLINICAL CORE

临床核心

• 批准号: 7035626
• 负责人: HARVEY Ira PASS
• 金额: $ 12.47万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7035626
• 关键词: asbestos; biomedical facility; cell line; environment related neoplasm /cancer; gene environment interaction; human tissue; lung; mesothelioma; microarray technology; simian virus 40; tissue /cell culture; tissue /cell preparation; tissue resource /registry

The Clinical Core housed at the Karmanos Cancer Institute is intended to be a resource for the program project as a whole and as a valuable source of biological materials necessary for the completion of the individual projects. The Clinical Core will be responsible for the collection, storage, and distribution of mesothelial cells and tissues, and mesothelioma tumors. The functions of the Clinical Core will be to serve as a resource for mesothelioma tumor tissue both snap frozen and paraffin embedded, and as a resource for asbestos-exposed pleura, lung, or peritoneum which is either snap frozen or paraffin embedded. The CORE will also serve as a resource for already established mesothelioma cell lines as well as an ongoing source of cultured human mesothelial cells from patients at the Karmanos Cancer Institute. New mesothelioma cell lines will be started prospectively from mesothleioma patients having resection. The Core will be responsible for the determining the SV40 status on these human mesothelial tissues, mesothelial cells, mesothelioma tumors and cultured mesothelioma cell lines in order to provide the appropriate reagents to the investigators. Tissue arrays for immunohistochemical validation of data will be constructed from paraffin embedded tumors and provided to the individual investigators. The Clinical Core will also coordinate the performance of asbestos lung content analysis from patients with mesothelioma for correlative data in the individual projects. It is estimated that 60-80 new mesothelioma cases per year will be seen at the Karmanos Cancer Institute during the course of the program project, and it is conservatively estimated that 20-30 of these will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used in Projects 1 and 3, and cell lines/cultures will be used in projects 2 and 3. By centralizing these services into a Core, the collection, storage, analysis, and distribution of tissues relevant to mesothelioma carcinogenesis will be better managed and coordinated for the entire Program Project.

设在卡马诺斯癌症研究所的临床核心计划旨在成为该计划的资源 该项目作为一个整体，并作为完成 个别项目。临床核心将负责收集、存储和分发 间皮细胞和组织以及间皮瘤。临床核心的职能将是服务于 作为间皮瘤肿瘤组织的速冻和石蜡包埋的来源，以及作为 暴露于石棉的胸膜、肺或腹膜，冰冻或石蜡包埋。其核心是 也将成为已经建立的间皮瘤细胞系的来源，以及正在进行的 从卡马诺斯癌症研究所的患者身上培养的人间皮细胞。新的间皮瘤细胞 将前瞻性地从接受切除的间皮瘤患者开始行手术。核心将负责 用于检测这些人间皮组织、间皮细胞、间皮瘤中的SV40状态 肿瘤和培养间皮瘤细胞系，以便为研究人员提供合适的试剂。 用于免疫组织化学数据验证的组织阵列将从石蜡包埋的肿瘤中构建 并提供给个人调查员。临床核心还将协调 间皮瘤患者肺石棉含量分析，以获得个别项目的相关数据。 据估计，卡马诺斯癌症研究所每年将出现60-80例新的间皮瘤病例 在方案项目过程中，保守估计其中20-30个将 作为新鲜/冷冻标本积累。石蜡包埋肿瘤将从所有病例中获得。肿瘤 样本将在项目1和3中使用，细胞系/培养将在项目2和3中使用。 将这些服务集中到一个核心中，收集、存储、分析和分发与以下相关的组织 间皮瘤的癌变将在整个计划项目中得到更好的管理和协调。